Open Filling Lines: 5 Bioburden Assumptions That Get You Cited

Open filling lines are where the most confident sterility claims meet the least forgiving inspections. A line can run for years without a single positive result and still carry assumptions about bioburden that no one has tested against a challenge. When an inspector arrives, those assumptions are exactly what gets probed. The gap between what a site believes about its open filling lines and what it can demonstrate is where citations start.

The pattern is consistent across findings. Sites do not usually get cited for missing a control. They get cited for relying on a bioburden assumption that has never been proven in the way the process actually runs. Below are five of the assumptions that most often turn into observations, and what closing each one looks like in practice.

1. Assuming interventions are covered because the media fill passed

A passing media fill is treated as proof that the interventions on an open filling line are safe. The problem is that media fills often rehearse a cleaner day than production sees. Routine interventions get counted, but the awkward corrective interventions, the ones that happen under pressure, are the ones that introduce risk. If the media fill program does not deliberately include worst case interventions at worst case frequency, the pass does not cover the operation that inspectors watch on the floor.

EU Annex 1 pushes sites toward interventions that reflect real production, including the difficult ones. Closing this gap means mapping every intervention the line actually performs, ranking them by contamination risk, and confirming that the qualification program challenges the hardest cases rather than the easiest.

2. Assuming first air protection holds on open filling lines

The idea that first air always reaches the exposed product and container is comforting and frequently untested. On open filling lines, an operator reaching across the critical zone, a poorly positioned tool, or a component guide can interrupt unidirectional airflow at exactly the moment it matters. Smoke studies are often filmed under static or ideal conditions, then filed as evidence for a dynamic reality they never captured.

The defensible position is airflow visualisation that includes the interventions and operator movements that occur during real filling, reviewed by people who can see when first air is broken. Where the study shows an interruption, the control is either the equipment design or the procedure, not the assumption.

3. Assuming environmental monitoring proves the bioburden picture

Environmental monitoring data that trends clean is often read as evidence that bioburden control is sound. Monitoring shows what the sampled locations caught at the sampled times. It does not automatically prove that the highest risk points on an open filling line are being watched, or that the sampling frequency matches when contamination is most likely.

Inspectors look at whether the monitoring plan follows a documented risk assessment or simply repeats historical locations. A strong contamination control strategy ties each sampling point to a specific risk on the line and explains why the location and frequency are enough. Our contamination control service exists to make that link explicit and inspection ready.

4. Assuming component and container bioburden is low enough

Stoppers, vials and the incoming components that feed an open filling line carry their own bioburden and endotoxin load. Sites sometimes assume that a supplier certificate settles the question. When the depyrogenation, washing or sterilisation step for those components has drifted, or the assumption about incoming load was never verified, the exposed product inherits the risk.

Closing this gap means treating incoming bioburden and endotoxin as controlled parameters with defined limits, verified by the site rather than accepted on trust.

5. Assuming operators behave the way the procedure describes

The final assumption is that the written aseptic technique is the technique used. Open filling lines depend heavily on operator behaviour, and behaviour drifts. Gowning shortcuts, slow movements that become fast, and hands that pass over the critical zone all erode the sterility assurance the procedure promises on paper.

The control is direct, documented observation of aseptic behaviour during real filling, with requalification tied to what is seen rather than to a calendar. When behaviour is watched and corrected, the procedure and the practice stay aligned, and the assumption stops being a liability.

Why these assumptions survive until an inspection

Each of these gaps shares a root cause. The control looks present on paper, so no one questions it until an inspector asks for the evidence behind it. A contamination control strategy that is built by design, rather than assembled from historical documents, forces each assumption to be stated, challenged and proven before the line runs. That is the difference between a site that explains its open filling lines with confidence and one that discovers its assumptions during a 483 discussion. You can see how we approach this in Contamination Control by Design.

Frequently asked questions

What is an open filling line?

An open filling line is an aseptic filling operation where the product, container or closure is exposed to the surrounding cleanroom environment during filling, rather than fully enclosed in a barrier system such as an isolator. Because the critical zone is open, it depends on airflow protection, environmental control and operator technique to maintain sterility.

Why do open filling lines attract more inspection focus?

The exposed critical zone means more of the sterility assurance rests on controls that can drift, such as interventions, airflow protection and operator behaviour. Inspectors focus there because it is where assumptions are most likely to go unproven.

How does EU Annex 1 change expectations for open filling lines?

Annex 1 expects a documented contamination control strategy that connects each control to a specific risk, and it expects interventions and airflow studies to reflect real production rather than idealised conditions. Assumptions that were once accepted now need demonstrated evidence.

How can a site prove its bioburden control is adequate?

By tying every monitoring point, intervention and incoming material limit to a documented risk assessment, challenging the hardest cases in qualification, and observing real aseptic behaviour. The goal is evidence that each control works in the operation as it actually runs.

Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.

Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.

If your open filling lines carry assumptions you have never had to defend, we can help you prove them before an inspector does. Talk to Pharmalliance about Contamination Control by Design or contact our team.